SRPT: Sarepta Therapeutics Inc. (DE) Stocks News on July 26, 2025

SRPT

Motley Fool

a month ago

2 Beaten-Down Stocks to Avoid

SRPT

Simply Wall St.

a month ago

Sarepta Therapeutics (NasdaqGS:SRPT) Faces Shipment Suspension Amid Safety Update

Sarepta Therapeutics Is Already Down 86% This Year. And The Other Shoe Just Dropped.

SRPT

Investor's Business Daily

a month ago

Sarepta Therapeutics Is Already Down 86% This Year. And The Other Shoe Just Dropped.

SRPT

Insider Monkey

a month ago

TD Cowen Downgrades Sarepta Therapeutics (SRPT) Stock to Hold, Reduces PT

SRPT

MT Newswires

a month ago

Sarepta Therapeutics' Elevidys Under Investigation by US FDA Following Patient Deaths

SRPT

Argus Research

a month ago

SRPT: Lowering target price to $15.00

Sarepta Viral Vector Gets FDA Platform Technology Designation

SRPT

Insider Monkey

a month ago

Sarepta Viral Vector Gets FDA Platform Technology Designation

SRPT

Insider Monkey

a month ago

Sarepta Therapeutics (SRPT) Tumbles 44% W/W as Analyst Cuts Price Target by 63%

Stocks Settle Mostly Lower as Chip Makers Fall

SRPT

Barchart

a month ago

Stocks Settle Mostly Lower as Chip Makers Fall

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

SRPT

Investor's Business Daily

a month ago

The FDA Shake-Up Continues, And Could Impact Genetic Medicines

SRPT

MT Newswires

a month ago

Sarepta Therapeutics Shares Decline After Downgrade From William Blair

Gene Therapy Stocks Fall Amid More Turmoil at FDA

SRPT

Barrons.com

a month ago

Gene Therapy Stocks Fall Amid More Turmoil at FDA

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.

SRPT

Barrons.com

a month ago

Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street.

SRPT

MT Newswires

a month ago

William Blair Downgrades Sarepta Therapeutics to Market Perform From Outperform

2 Growth Stocks with All-Star Potential and 1 to Ignore

SRPT

StockStory

a month ago

2 Growth Stocks with All-Star Potential and 1 to Ignore

SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls

SRPT

TipRanks

a month ago

SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls

Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.

SRPT

Barrons.com

a month ago

Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.

Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls

SRPT

TipRanks

a month ago

Roku upgraded, Sarepta downgraded: Wall Street’s top analyst calls

SRPT

MT Newswires

a month ago

Goldman Sachs Downgrades Sarepta Therapeutics to Neutral From Buy, Adjusts Price Target to $29 From $100

SRPT

MT Newswires

a month ago

TD Cowen Downgrades Sarepta Therapeutics to Hold From Buy, Cuts Price Target to $24 From $62

SRPT

Simply Wall St.

a month ago

Sarepta Therapeutics (NasdaqGS:SRPT) SRP-9003 Gene Therapy Earns FDA Platform Technology Designation

Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls

SRPT

TipRanks

a month ago

Cisco upgraded, CoreWeave downgraded: Wall Street’s top analyst calls

SRPT

Zacks

a month ago

Company News for Jun 17, 2025

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

SRPT

TipRanks

a month ago

Morning Movers: Sage Therapeutics surges after deal to be acquired by Supernus

SRPT

MT Newswires

a month ago

Deutsche Bank Halves Price Target on Sarepta Therapeutics to $25 From $50, Keeps Hold Rating

SRPT

MT Newswires

a month ago

Wolfe Research Initiates Coverage on Sarepta Therapeutics With Peer Perform Rating

Stocks to Watch Recap: U.S. Steel, Kraft Heinz, Circle, Warner Bros.

SRPT

The Wall Street Journal

a month ago

Stocks to Watch Recap: U.S. Steel, Kraft Heinz, Circle, Warner Bros.

Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies

SRPT

Investor's Business Daily

a month ago

Sarepta Crashes To Nine-Year Low After A Second Gene Therapy Patient Dies

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More

SRPT

Barrons.com

a month ago

These Stocks Moved the Most Today: Sarepta, AMD, Tesla, U.S. Steel, Roku, Sage Therapeutics, and More

Second patient death reported with gene therapy for muscular dystrophy

SRPT

Associated Press Finance

a month ago

Second patient death reported with gene therapy for muscular dystrophy

SRPT

Investing.com

a month ago

Sarepta down analysts flag risks after second Elevidys-linked death

SRPT

MT Newswires

a month ago

Sector Update: Health Care

5 Things to Know Before the Stock Market Opens

SRPT

Investopedia

a month ago

5 Things to Know Before the Stock Market Opens

Sarepta and Roche halt DMD gene therapy’s use after second death

SRPT

Pharmaceutical Technology

a month ago

Sarepta and Roche halt DMD gene therapy’s use after second death

SRPT

MT Newswires

a month ago

Top Premarket Decliners

SRPT

MT Newswires

a month ago

HC Wainwright Downgrades Sarepta Therapeutics to Sell From Neutral, Adjusts PT to $10 From $40

SRPT

MT Newswires

a month ago

Piper Sandler Downgrades Sarepta Therapeutics to Neutral From Overweight, Adjusts PT to $36 From $70

SRPT

MT Newswires

a month ago

BMO Capital Downgrades Sarepta Therapeutics to Market Perform From Outperform, Adjusts PT to $70 From $120

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

SRPT

Business Wire

a month ago

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

SRPT

Argus Research

2 months ago

SRPT: What does Argus have to say about SRPT?

SRPT

Insider Monkey

2 months ago

Sarepta Therapeutics’ (SRPT) Rating Downgrade Dents Share Price

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

SRPT

StockStory

2 months ago

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

SRPT

MT Newswires

2 months ago

Sarepta Likely to Meet Revised Guidance, Oppenheimer Says

SRPT

Simply Wall St.

2 months ago

Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval

CrowdStrike and McDonald’s downgraded: Wall Street’s top analyst calls

SRPT

TipRanks

2 months ago

CrowdStrike and McDonald’s downgraded: Wall Street’s top analyst calls

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Shares Rise After Upgrade From Scotiabank

SRPT

MT Newswires

2 months ago

Scotiabank Upgrades Sarepta Therapeutics to Sector Outperform From Sector Perform, $80 Price Target

The FDA granted Sarepta’s rAAVrh74 Viral Vector a Platform Technology Designation

SRPT

Insider Monkey

2 months ago

The FDA granted Sarepta’s rAAVrh74 Viral Vector a Platform Technology Designation

SRPT

Zacks

2 months ago

Why Is Sarepta Therapeutics (SRPT) Up 7.7% Since Last Earnings Report?

FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector

SRPT

Zacks

2 months ago

FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector

FDA to use new review tool on Sarepta’s gene therapy work

SRPT

BioPharma Dive

2 months ago

FDA to use new review tool on Sarepta’s gene therapy work

SRPT

MT Newswires

2 months ago

Sarepta Receives FDA Platform Technology Designation for Viral Vector in SRP-9003

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

SRPT

Business Wire

2 months ago

U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4

1 Value Stock on Our Buy List and 2 to Approach with Caution

SRPT

StockStory

2 months ago

1 Value Stock on Our Buy List and 2 to Approach with Caution

1 Volatile Stock to Own for Decades and 2 to Keep Off Your Radar

SRPT

StockStory

2 months ago

1 Volatile Stock to Own for Decades and 2 to Keep Off Your Radar

SRPT

Insider Monkey

2 months ago

Was Jim Cramer Right About Sarepta Therapeutics Inc. (SRPT)?

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study

SRPT

BioPharma Dive

2 months ago

FDA advisers pan Pfizer’s PARP drug; Sarepta to resume Duchenne study

SRPT

Simply Wall St.

2 months ago

Sarepta Therapeutics (NasdaqGS:SRPT) Continues Phase 3 Study of ELEVIDYS Gene Therapy in Duchenne

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

SRPT

Business Wire

2 months ago

Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy

High Growth Tech Stocks In The US Market To Watch

SRPT

Simply Wall St.

2 months ago

High Growth Tech Stocks In The US Market To Watch

3 Stocks Investors May Be Undervaluing By Up To 43.5%

SRPT

Simply Wall St.

2 months ago

3 Stocks Investors May Be Undervaluing By Up To 43.5%

SRPT

StockStory

2 months ago

SRPT Q1 Earnings Call: Sarepta Adjusts Guidance After Safety Event and Administrative Delays

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy

SRPT

Clinical Trials Arena

2 months ago

Sarepta reports outcomes from trial of Duchenne muscular dystrophy therapy

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

SRPT

Business Wire

2 months ago

Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

SRPT

Business Wire

2 months ago

Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

SRPT

StockStory

2 months ago

2 Healthcare Stocks to Keep an Eye On and 1 to Ignore

SRPT

Simply Wall St.

2 months ago

Bearish: Analysts Just Cut Their Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Revenue and EPS estimates

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses

SRPT

StockStory

2 months ago

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $29.00

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Says Duchenne Muscular Dystrophy Treatment Gets Approval in Japan

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

SRPT

Business Wire

2 months ago

Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy

2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying

SRPT

Motley Fool

2 months ago

2 Stocks Near Their 52-Week Lows That Still Aren't Worth Buying

SRPT

Insider Monkey

3 months ago

Sarepta Therapeutics, Inc. (SRPT): Among Billionaire Glenn Russell Dubin’s Stock Picks with Huge Upside Potential

Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz

SRPT

TipRanks

3 months ago

Trump announces trade deal, BoE lowers Bank Rate: Morning Buzz

SRPT

Insider Monkey

3 months ago

Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

SRPT

Business Wire

3 months ago

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

Sarepta price target lowered to $125 from $183 at Needham

SRPT

TipRanks

3 months ago

Sarepta price target lowered to $125 from $183 at Needham

SRPT

MT Newswires

3 months ago

UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating

Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

SRPT

Simply Wall St.

3 months ago

Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

SRPT

Insider Monkey

3 months ago

Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks

SRPT

StockStory

3 months ago

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks

SRPT

StockStory

3 months ago

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low

SRPT

Investor's Business Daily

3 months ago

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low

SRPT

StockStory

3 months ago

Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why

Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire.

SRPT

Barrons.com

3 months ago

Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire.

SRPT

Thomson Reuters StreetEvents

3 months ago

Q1 2025 Sarepta Therapeutics Inc Earnings Call

SRPT

Zacks

3 months ago

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales

SRPT

Pharmaceutical Technology

3 months ago

Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales

SRPT

GuruFocus.com

3 months ago

Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...

SRPT

Zacks

3 months ago

Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics

SRPT

StockStory

3 months ago

Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%

SRPT

Zacks

3 months ago

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

SRPT

MT Newswires

3 months ago

Sarepta Therapeutics Swings to Non-GAAP Q1 Loss; Shares Tumble After Hours

SRPT

StockStory

3 months ago

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow

Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks

SRPT

TipRanks

3 months ago

Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks

1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution

SRPT

StockStory

3 months ago

1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution

Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SRPT

Zacks

3 months ago

Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SRPT

Insider Monkey

3 months ago

Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now

SRPT

Zacks

3 months ago

Latest Sarepta Therapeutics Inc. (DE) (SRPT) News on July 26, 2025

Share on Social Networks: